Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Case Report, J Trauma Stress Disor Treat Vol: 3 Issue: 2
Clozapine for Treatment- Resistant Post-Traumatic Stress Disorder (PTSD)
| Harmony Raylen Abejuela1,2,3*, Fe Erlita Festin1,2 and Lynn Es DeLisi1 | |
| 1Veterans Affairs (VA) Boston Healthcare System, USA | |
| 2Department of Psychiatry, Harvard Medical School, USA | |
| 2Harvard South Shore (HSS) Psychiatry Residency Training Program, USA | |
| Corresponding author : Harmony Raylen Abejuela Harvard South Shore (HSS), Psychiatry Residency Training Program, VA Boston Healthcare System (116 A-7), 940 Belmont Street, Brockton, MA 02301, USA Tel: 774-826-2458; Fax: 774-826-1859 E-mail: harmonyraylen@hotmail.com |
|
| Received: July 22, 2013 Accepted: February 28, 2014 Published: March 11, 2014 | |
| Citation: Abejuela HR, Festin FE, DeLisi LE (2014) Clozapine for Treatment-Resistant Post-Traumatic Stress Disorder (PTSD). J Trauma Stress Disor Treat 3:2. doi:10.4172/2324-8947.1000120 |
Abstract
Clozapine for Treatment- Resistant Post-Traumatic Stress Disorder (PTSD)
Clozapine is approved by the Food and Drug Administration (FDA) for treatment of schizophrenia, has been used off-label for treatment of patients with bipolar disorder, and has been shown to reduce suicidal ideation. However, because of its various adverse effects, clozapine has not been adequately explored for treatment of other psychiatric disorders, particularly in suicidal post-traumatic stress disorder (PTSD) patients. Suicidal PTSD patients are challenging, given their multiple inpatient psychiatric hospitalizations and numerous failed medication trials. It is possible that clozapine may be a useful treatment for suicidal PTSD patients, particularly when other treatments have failed.
